Treatment of hypertension by increasing impaired endothelial TRPV4-KCa2.3 interaction
- PMID: 28899928
- PMCID: PMC5666316
- DOI: 10.15252/emmm.201707725
Treatment of hypertension by increasing impaired endothelial TRPV4-KCa2.3 interaction
Abstract
The currently available antihypertensive agents have undesirable adverse effects due to systemically altering target activity including receptors, channels, and enzymes. These effects, such as loss of potassium ions induced by diuretics, bronchospasm by beta-blockers, constipation by Ca2+ channel blockers, and dry cough by ACEI, lead to non-compliance with therapies (Moser, 1990). Here, based on new hypertension mechanisms, we explored a new antihypertensive approach. We report that transient receptor potential vanilloid 4 (TRPV4) interacts with Ca2+-activated potassium channel 3 (KCa2.3) in endothelial cells (ECs) from small resistance arteries of normotensive humans, while ECs from hypertensive patients show a reduced interaction between TRPV4 and KCa2.3. Murine hypertension models, induced by high-salt diet, N(G)-nitro-l-arginine intake, or angiotensin II delivery, showed decreased TRPV4-KCa2.3 interaction in ECs. Perturbation of the TRPV4-KCa2.3 interaction in mouse ECs by overexpressing full-length KCa2.3 or defective KCa2.3 had hypotensive or hypertensive effects, respectively. Next, we developed a small-molecule drug, JNc-440, which showed affinity for both TRPV4 and KCa2.3. JNc-440 significantly strengthened the TRPV4-KCa2.3 interaction in ECs, enhanced vasodilation, and exerted antihypertensive effects in mice. Importantly, JNc-440 specifically targeted the impaired TRPV4-KCa2.3 interaction in ECs but did not systemically activate TRPV4 and KCa2.3. Together, our data highlight the importance of impaired endothelial TRPV4-KCa2.3 coupling in the progression of hypertension and suggest a novel approach for antihypertensive drug development.
Keywords: KCa2.3; TRPV4; artery; endothelium; hypertension.
© 2017 The Authors. Published under the terms of the CC BY 4.0 license.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5666316/bin/EMMM-9-1491-g002.gif)
- A
The hypothesis investigated in this study was that endothelial TRPV4‐KCa2.3 interaction modulates blood pressure, and impairment of the interaction is related to hypertension. So, strengthening the interaction with a small‐molecule drug, JNc‐440, would show antihypertensive effects.
- B
Immuno‐FRET experiments in arterial sections from normotensive and hypertensive humans. Left: representative figures for FRET. White dotted line, autofluorescence of elastin underneath the endothelium; right: analysis of 21 normotensive and 15 hypertensive individuals (# P < 0.0001, unpaired t‐test vs. control). Scale bar, 20 μm.
- C–E
Immuno‐FRET experiments in arterial sections from (C) mice on a high‐salt diet (8% NaCl), (D) mice with L‐NNA intake (0.5 g/l in the drinking water), or (E) mice with AngII delivery (infused at 500 ng/kg/min) (# P < 0.0001, unpaired t‐test vs. control).
- F
Fluorescent K+ efflux results showing the TRPV4 agonist GSK1016790A (GSK)‐induced K+ efflux in primary cultured ECs from normal mice and mice on a high‐salt diet (left). Six mice were tested for each treatment and analyzed (right). ECs from TRPV4‐knockout (KO) mice were used as negative controls [# P < 0.0001, two‐way ANOVA (GSK 30 nM, high salt vs. control; GSK 100 nM, high salt vs. control)].
- G
Modulation of vasodilation by GSK1016790A (GSK), acetylcholine (ACh), and sodium nitroprusside (SNP). Left: vasodilation assays by wire myograph showing GSK1016790A (GSK)‐induced dilation in freshly isolated arterial segments from normal mice and mice on a high‐salt diet. Second from left: five mice were tested for each treatment and statistically analyzed (# P < 0.0001 vs. control, two‐way ANOVA). Rightmost two panels: statistical data of vasodilation for ACh (n = 3/treatment) and SNP (n = 3/treatment) treatment in freshly isolated arterial segments from normal mice and mice on a high‐salt diet (*P < 0.0001, # P = 0.0004 vs. control, two‐way ANOVA).
- H
FRET in HEK cells co‐expressing CFP‐tagged TRPV4 and YFP‐tagged KCa2.3 showing the critical role of the AR2 and C‐terminal 17‐amino acid (17C) regions in the interaction. TRPV4 was deleted at the different AR and CaMBD regions, whereas KCa2.3 was deleted at the 17C, α1, α2, Loop, and CAMBD regions. NC, negative control, assessed in cells co‐expressing CFP and YFP as separate molecules; PC, positive control, assessed in cells expressing YFP‐CFP dimer (# P < 0.0001 vs. wild‐type control (TRPV4‐KCa2.3), one‐way ANOVA).
- I
Stochastic optical reconstruction images of the indicated constructs in overexpressing HEK cells (scale bars, 10 μm).
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5666316/bin/EMMM-9-1491-g003.gif)
- A–H
Mice were intravenously injected with AAV‐Flt1‐KCa2.3 and the AAV‐Flt1 vector served as a control. (A) Representative en face (left) and cross‐sectional (right) fluorescence images of AAV‐Flt1‐KCa2.3 or vector (flag‐tag) expression in AAV‐Flt1‐infected mice. Green, autofluorescence of elastin underneath the endothelium (excitation, 488 nm); red, anti‐flag. Scale bars, 10 μm. (B) Seven mice were tested for the effects of AAV‐Flt1‐KCa2.3 or vector in immuno‐FRET experiments (# P < 0.0001 vs. control, unpaired t‐test). (C, F) K+ efflux from primary cultured ECs (# P < 0.0001 vs. control, unpaired t‐test). (D, G) Vasodilation assays by wire myography (GSK1016790A (GSK) and ACh in freshly isolated arterial segments) (*P = 0.047, # P < 0.0001 vs. control, two‐way ANOVA). (E, H) Time course of the changes in mean arterial pressure (∆MAP) in wild‐type (C–E) and TRPV4‐knockout (KO) (F–H) mice after tail injection of AAV‐Flt1‐KCa2.3, AAV‐Flt1 vector, or vehicle (injection solution).
- I–O
Mice were intravenously injected with AAV‐Flt1‐KCa2.3‐17C; the AAV‐Flt1 vector served as the control. (I) Mice were tested for effects of AAV‐Flt1‐KCa2.3‐17C or vector with immuno‐FRET experiments (# P < 0.0001 vs. control, unpaired t‐test). (J, M) K+ efflux from primary cultured ECs (# P < 0.0001 vs. control, unpaired t‐test). (K, N) Vasodilation assays by wire myography (GSK1016790A (GSK) and ACh) in freshly isolated arterial segments) (*P = 0.004, # P < 0.0001 vs. control, two‐way ANOVA). (L, O) Time course of the changes in mean arterial pressure (∆MAP) in wild‐type (J–L) and TRPV4‐knockout (KO) (M–O) mice after tail injection of AAV‐Flt1‐KCa2.3‐17C, AAV‐Flt1 vector, or vehicle (injection solution).
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5666316/bin/EMMM-9-1491-g004.gif)
- A
Left: structural formula of JNc‐440. Right: affinity of JNc‐440 for both TRPV4 and KCa2.3. Biotinylated JNc‐440 (JNc‐440‐biotin) pulled down TRPV4 or KCa2.3 in primary cultured ECs.
- B–G
(B) Immuno‐FRET experiments in arterial sections, (C) K+ efflux from primary cultured ECs, (D) vasodilation assays by wire myography (GSK and ACh) in freshly isolated arterial segments, and (E) mean arterial pressure. (F) Effect of JNc‐440 on blood pressure in normotensive mice. (G) Effect of JNc‐440 (1 mg/kg; daily for 1 week) on blood pressure in TRPV4‐knockout (KO) mice treated with a high‐salt diet, L‐NNA, or AngII. WT mice were treated with a high‐salt diet, L‐NNA, or AngII and then intravenously injected with JNc‐440 (1 mg/kg) or vehicle for 2 h (B–F) or daily for 1 week (G). Data are mean ± SD. (B, C) # P < 0.0001 vs. control, unpaired t‐test. (D) *P = 0.025 (high‐salt diet), *P = 0.008 (L‐NNA treatment), or *P = 0.021 (AngII treatment), # P < 0.0001 vs. control, two‐way ANOVA. (E) *P = 0.001, # P < 0.0001 vs. control, two‐way ANOVA.
Similar articles
-
Exercise restores impaired endothelium-derived hyperpolarizing factor-mediated vasodilation in aged rat aortic arteries via the TRPV4-KCa2.3 signaling complex.Clin Interv Aging. 2019 Sep 2;14:1579-1587. doi: 10.2147/CIA.S220283. eCollection 2019. Clin Interv Aging. 2019. PMID: 31564840 Free PMC article.
-
Endothelial TRPV4-eNOS coupling as a vital therapy target for treatment of hypertension.Br J Pharmacol. 2022 May;179(10):2297-2312. doi: 10.1111/bph.15755. Epub 2022 Jan 28. Br J Pharmacol. 2022. PMID: 34822720
-
Endothelial SK3 channel-associated Ca2+ microdomains modulate blood pressure.Am J Physiol Heart Circ Physiol. 2016 May 1;310(9):H1151-63. doi: 10.1152/ajpheart.00787.2015. Epub 2016 Mar 4. Am J Physiol Heart Circ Physiol. 2016. PMID: 26945080 Free PMC article.
-
TRPV4 and the regulation of vascular tone.J Cardiovasc Pharmacol. 2013 Feb;61(2):113-9. doi: 10.1097/FJC.0b013e318279ba42. J Cardiovasc Pharmacol. 2013. PMID: 23107877 Free PMC article. Review.
-
Role of TRPV4 channel in vasodilation and neovascularization.Microcirculation. 2021 Aug;28(6):e12703. doi: 10.1111/micc.12703. Epub 2021 May 24. Microcirculation. 2021. PMID: 33971061 Review.
Cited by
-
Single-Cell RNA-Seq Reveals Coronary Heterogeneity and Identifies CD133+TRPV4high Endothelial Subpopulation in Regulating Flow-Induced Vascular Tone in Mice.Arterioscler Thromb Vasc Biol. 2024 Mar;44(3):653-665. doi: 10.1161/ATVBAHA.123.319516. Epub 2024 Jan 25. Arterioscler Thromb Vasc Biol. 2024. PMID: 38269590 Free PMC article.
-
Cognitive enhancing effects of pazopanib in D‑galactose/ovariectomized Alzheimer's rat model: insights into the role of RIPK1/RIPK3/MLKL necroptosis signaling pathway.Inflammopharmacology. 2023 Oct;31(5):2719-2729. doi: 10.1007/s10787-023-01269-y. Epub 2023 Jul 17. Inflammopharmacology. 2023. PMID: 37458952 Free PMC article.
-
Histone deacetylase inhibitors (HDACi) increase expression of KCa2.3 (SK3) in primary microvascular endothelial cells.Am J Physiol Cell Physiol. 2022 Mar 1;322(3):C338-C353. doi: 10.1152/ajpcell.00409.2021. Epub 2022 Jan 19. Am J Physiol Cell Physiol. 2022. PMID: 35044858 Free PMC article.
-
Single-cell analysis of salt-induced hypertensive mouse aortae reveals cellular heterogeneity and state changes.Exp Mol Med. 2021 Dec;53(12):1866-1876. doi: 10.1038/s12276-021-00704-w. Epub 2021 Dec 3. Exp Mol Med. 2021. PMID: 34862465 Free PMC article.
-
The Transient Receptor Potential Vanilloid 4 Channel and Cardiovascular Disease Risk Factors.Front Physiol. 2021 Sep 20;12:728979. doi: 10.3389/fphys.2021.728979. eCollection 2021. Front Physiol. 2021. PMID: 34616307 Free PMC article. Review.
References
-
- Adebiyi A, Thomas‐Gatewood CM, Leo MD, Kidd MW, Neeb ZP, Jaggar JH (2012) An elevation in physical coupling of type 1 inositol 1,4,5‐trisphosphate (IP3) receptors to transient receptor potential 3 (TRPC3) channels constricts mesenteric arteries in genetic hypertension. Hypertension 60: 1213–1219 - PMC - PubMed
-
- Barron LA, Giardina JB, Granger JP, Khalil RA (2001) High‐salt diet enhances vascular reactivity in pregnant rats with normal and reduced uterine perfusion pressure. Hypertension 38: 730–735 - PubMed
-
- Brahler S, Kaistha A, Schmidt VJ, Wolfle SE, Busch C, Kaistha BP, Kacik M, Hasenau AL, Grgic I, Si H, et al. (2009) Genetic deficit of SK3 and IK1 channels disrupts the endothelium‐derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation 119: 2323–2332 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous